TICKERNERD
Menu
MGNXMGNXHealthcare · Biotechnology

MGNX Stock Forecast: MacroGenics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$4.00
+0.76% on the day

The 7 Wall Street analysts covering MacroGenics, Inc. hold a median 12-month price target of $8.5 — +112.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$254.8M
Ticker Nerd rank
65 / 100
Median analyst target
$8.50
Analysts covering
7
Revenue$32.8M+47.6% y/y
Operating income−$13.9M
Net income$19.5M
Free cash flow−$41.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.9%
1M
+2.0%
YTD
+148.4%
1Y
+142.4%
From 52W high
−17.7%
From 52W low
+200.8%
$1.33
$4.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MGNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MacroGenics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Value
78
Size
65
Quality
59
Growth
58
Accruals
53
Revisions
45
Volatility
35
Issuance
23

Momentum (96): The shares have been drifting up relative to others.

Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MGNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MGNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26MGNXHigh $11.00Median $8.50Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
3 Buy4 Hold0 Sell
Low $4.00Median $8.50High $11.00

The green dot is the last close — the median target sits +112.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026B. Riley SecuritiesMaintainsBuy—
17 Aug 2026B. Riley SecuritiesMaintainsBuy$9.00 → $11
20 Apr 2026BarclaysMaintainsOverweight—
20 Apr 2026BarclaysMaintainsOverweight$4.00 → $6.00
10 Apr 2026B. Riley SecuritiesUpgradeBuy—
10 Mar 2026BarclaysMaintainsOverweight—
3 Nov 2025HC Wainwright & Co.ReiteratesNeutral—
17 Sept 2025BarclaysAssumesOverweight$3.00
15 Aug 2025Leerink PartnersMaintainsOutperform—
20 May 2025B. Riley SecuritiesMaintainsNeutral—
14 May 2025BarclaysMaintainsOverweight—
14 May 2025StifelMaintainsHold—
25 Mar 2025HC Wainwright & Co.MaintainsNeutral—
7 Nov 2024JMP SecuritiesDowngradeMarket Perform—
6 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
18 Sept 2024HC Wainwright & Co.ReiteratesNeutral—
21 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
15 Aug 2024CitigroupMaintainsBuy—
7 Aug 2024BMO CapitalMaintainsMarket Perform—
1 Aug 2024BTIGDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MGNX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MGNX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, MacroGenics, Inc. returned +142.4% against +17.5% for the S&P 500, dividends included.

MGNX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26MGNXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MGNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

MacroGenics, Inc. (MGNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
25.3×

Cheaper than 30% of US stocks

Price / sales
1.5×

Cheaper than 61% of US stocks

Price / book
5.9×

Cheaper than 17% of US stocks

EV / EBITDA
−3.6×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
378.0%

Higher than 97% of US stocks

Earnings growth (YoY)
47.6%

Higher than 74% of US stocks

Gross margin
54.1%

Higher than 67% of US stocks

Operating margin
−42.2%

Higher than 18% of US stocks

Net margin
−8.3%

Higher than 21% of US stocks

Returns & dividend
Return on equity
−225.8%

Higher than 6% of US stocks

Return on assets
−8.1%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MacroGenics, Inc. (MGNX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MacroGenics, Inc. has a market value of $254.8M and an enterprise value of $116.6M.

  • Revenue in the twelve months to 30 June 2026: $167.7M. The latest quarter grew 378.0% year on year.

  • Net income over the same four quarters: −$14.6M, a −8.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$65.5M.

  • Shares outstanding: 63.6M.

  • Trailing P/E: 25.3×; forward P/E: −2.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • MacroGenics, Inc. employs 293 people — $572K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

MGNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MGNXMacroGenics, Inc.$254.8M
65
PRQRProQR Therapeutics NV$256.8M
43
LCTXLineage Cell Therapeutics, Inc.$251.6M
55
FHTXFoghorn Therapeutics, Inc.$258.9M
69
TRDAEntrada Therapeutics, Inc.$264.0M
54
VRXAVERAXA Biotech AG$243.8M
20
AVXLAnavex Life Sciences Corp.$242.8M
25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MacroGenics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MGNX news & analysis

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 9 Sept 2026neutral

MacroGenics announced that President and CEO Eric Risser will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, at 9:30 a.m. ET. The company focuses on developing antibody-based cancer therapies.

Why it matters — This participation gives MGNX watchers an opportunity to hear directly from the company's CEO regarding its oncology pipeline at a major investment conference.

MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead

Seeking Alpha · 9 Sept 2026positive

Seeking Alpha highlighted MacroGenics as an inexpensive biotech trading at a discount to its $327 million cash position, with a differentiated pipeline spanning antibody drug conjugates, T-cell engagers, and lorigerlimab. The article notes multiple near-term catalysts and suggests the company's partnership potential is underappreciated given its negative enterprise value.

Why it matters — MGNX watchers would care because the article points to near-term pipeline catalysts and an underappreciated partnership opportunity that could influence the company's valuation.

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research · 20 Aug 2026neutral

The article compares MacroGenics (MGNX) and CareDx (CDNA) stock performance so far this year relative to their medical-sector peers. The headline poses the question of whether MGNX is outpacing its medical peers, addressing the stock's year-to-date performance within its sector.

Why it matters — MGNX watchers would care because the comparison indicates where the company's stock currently stands against its sector peers this year, signaling its relative performance in the market.

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 13 Aug 2026positive

MacroGenics reported a Q2 loss of $0.27 per share, which was narrower than the Zacks Consensus Estimate of a $0.40 loss and improved from the $0.57 loss in the year-ago quarter. The company's quarterly results lagged revenue estimates.

Why it matters — MGNX watchers would note that the company's per-share loss narrowed significantly versus both analyst expectations and the prior-year quarter, even as revenue came up short of estimates.

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

GlobeNewsWire · 13 Aug 2026positive

MacroGenics reported its financial results for the quarter ended June 30, 2026, and highlighted recent corporate and pipeline progress. The headline notes a streamlined operating model and strengthened financial position.

Why it matters — The update offers MGNX watchers an overview of the company's operational and financial standing as it continues advancing its antibody-based cancer therapeutics pipeline.

FAQ

Frequently asked questions about MGNX stock

What is the MGNX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering MacroGenics, Inc. have a median 12-month price target of $8.5, with estimates ranging from $4 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MGNX stock a buy right now?

Of the 7 analysts covering MacroGenics, Inc., 3 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MacroGenics, Inc. 65 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MGNX?

As at 12 Sept 2026, MacroGenics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will MGNX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +112.5% from the last close, and Ticker Nerd's factor model ranks MacroGenics, Inc. 65 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MGNX stock forecast for 2030?

No analyst covering MacroGenics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $11 over the next 12 months.

How has MGNX stock performed over the past year?

MacroGenics, Inc. returned +142.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MacroGenics, Inc. do?

MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer.

What is the latest news on MGNX?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference". MacroGenics announced that President and CEO Eric Risser will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, at 9:30 a.m. ET. The company focuses on developing antibody-based cancer therapies.

Company

About MacroGenics, Inc.

MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer. Its current portfolio centers on advanced biologics platforms, including antibody-drug conjugates, bispecific checkpoint antibodies, and next-generation T-cell engagers, which support a pipeline of product candidates in clinical testing. The company’s work includes therapies designed to target specific tumor markers and modulate immune responses across a range of oncology settings. MacroGenics also maintains collaborations with other biotechnology and pharmaceutical companies to support development across its programs. Headquartered in Rockville, Maryland, MacroGenics plays a specialized role in the oncology market by advancing precision antibody technologies intended for use in difficult-to-treat cancers.

CEO Mr. Eric Blasius Risser · 293 employees · United States · https://www.macrogenics.com